Humoral immune response of BBIBP COVID-19 vaccination before and after the booster immunization.

ABSTRACT:

Background

The inactivated Sinopharm/BBIBP COVID-19 vaccine has been widely used in the world and has joined the COVAX vaccine supply program for developing countries. It is also well adapted for usage in low- and middle-income nations due to their low storage requirements.

Objective

This study aims to report on the kinetics, durability, and neutralizing ability of the induced immunity of the BBIBP vaccine, and the intensified antibody response elicited by the booster.

Methods

A total of 353 healthy adult participants, aged 20-74 years, were recruited in this multicenter study. A standard dose of the BBIBP vaccine was administered (Month 0), followed by a second standard dose (Month 1), and a booster dose (after Month 7). Vaccine-induced virus-specific antibody levels

SUBMITTER: Cheng ZJ 

PROVIDER: S-EPMC9111230 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature